In vitro assessment of the antifungal and paradoxical activity of different echinocandins against Candida tropicalis biofilms

References

1. Bachmann S. P., VandeWalle K., Ramage G., Patterson T. F., Wickes B. L., Graybill J. R., López-Ribot J. L. 2002; In vitro activity of caspofungin against Candida albicans biofilms. Antimicrob Agents Chemother 46:3591–3596 [CrossRef][PubMed]
   [Google Scholar]
2. Bassetti M., Righi E., Costa A., Fasce R., Molinari M. P., Rosso R., Pallavicini F. B., Viscoli C. 2006; Epidemiological trends in nosocomial candidemia in intensive care. BMC Infect Dis 6:21 [CrossRef][PubMed]
   [Google Scholar]
3. Bizerra F. C., Melo A. S., Katchburian E., Freymüller E., Straus A. H., Takahashi H. K., Colombo A. L. 2011; Changes in cell wall synthesis and ultrastructure during paradoxical growth effect of caspofungin on four different Candida species. Antimicrob Agents Chemother 55:302–310 [CrossRef][PubMed]
   [Google Scholar]
4. Chamilos G., Lewis R. E., Albert N., Kontoyiannis D. P. 2007; Paradoxical effect of echinocandins across Candida species in vitro: evidence for echinocandin-specific and Candida species-related differences. Antimicrob Agents Chemother 51:2257–2259 [CrossRef][PubMed]
   [Google Scholar]
5. Choi H. W., Shin J. H., Jung S. I., Park K. H., Cho D., Kee S. J., Shin M. G., Suh S. P., Ryang D. W. 2007; Species-specific differences in the susceptibilities of biofilms formed by Candida bloodstream isolates to echinocandin antifungals. Antimicrob Agents Chemother 51:1520–1523 [CrossRef][PubMed]
   [Google Scholar]
6. Cocuaud C., Rodier M. H., Daniault G., Imbert C. 2005; Anti-metabolic activity of caspofungin against Candida albicans and Candida parapsilosis biofilms. J Antimicrob Chemother 56:507–512 [CrossRef][PubMed]
   [Google Scholar]
7. Ferreira J. A., Carr J. H., Starling C. E., de Resende M. A., Donlan R. M. 2009; Biofilm formation and effect of caspofungin on biofilm structure of Candida species bloodstream isolates. Antimicrob Agents Chemother 53:4377–4384 [CrossRef][PubMed]
   [Google Scholar]
8. Fleischhacker M., Radecke C., Schulz B., Ruhnke M. 2008; Paradoxical growth effects of the echinocandins caspofungin and micafungin, but not of anidulafungin, on clinical isolates of Candida albicans and C. dubliniensis. Eur J Clin Microbiol Infect Dis 27:127–131 [CrossRef][PubMed]
   [Google Scholar]
9. Garcia-Effron G., Park S., Perlin D. S. 2009; Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. Antimicrob Agents Chemother 53:112–122 [CrossRef][PubMed]
   [Google Scholar]
10. Jacobson M. J., Piper K. E., Nguyen G., Steckelberg J. M., Patel R. 2008; In vitro activity of anidulafungin against Candida albicans biofilms. Antimicrob Agents Chemother 52:2242–2243 [CrossRef][PubMed]
    [Google Scholar]
11. Jacobson M. J., Steckelberg K. E., Piper K. E., Steckelberg J. M., Patel R. 2009; In vitro activity of micafungin against planktonic and sessile Candida albicans isolates. Antimicrob Agents Chemother 53:2638–2639 [CrossRef][PubMed]
    [Google Scholar]
12. Kuhn D. M., George T., Chandra J., Mukherjee P. K., Ghannoum M. A. 2002; Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob Agents Chemother 46:1773–1780 [CrossRef][PubMed]
    [Google Scholar]
13. Melo A. S., Colombo A. L., Arthington-Skaggs B. A. 2007; Paradoxical growth effect of caspofungin observed on biofilms and planktonic cells of five different Candida species. Antimicrob Agents Chemother 51:3081–3088 [CrossRef][PubMed]
    [Google Scholar]
14. Miceli M. H., Bernardo S. M., Lee S. A. 2009a; In vitro analyses of the combination of high-dose doxycycline and antifungal agents against Candida albicans biofilms. Int J Antimicrob Agents 34:326–332 [CrossRef][PubMed]
    [Google Scholar]
15. Miceli M. H., Bernardo S. M., Lee S. A. 2009b; In vitro analysis of the occurrence of a paradoxical effect with different echinocandins and Candida albicans biofilms. Int J Antimicrob Agents 34:500–502 [CrossRef][PubMed]
    [Google Scholar]
16. Nucci M., Queiroz-Telles F., Tobón A. M., Restrepo A., Colombo A. L. 2010; Epidemiology of opportunistic fungal infections in Latin America. Clin Infect Dis 51:561–570 [CrossRef][PubMed]
    [Google Scholar]
17. Odabasi Z., Paetznick V., Rex J. H., Ostrosky-Zeichner L. 2007; Effects of serum on in vitro susceptibility testing of echinocandins. Antimicrob Agents Chemother 51:4214–4216 [CrossRef][PubMed]
    [Google Scholar]
18. Pfaller M. A., Boyken L., Hollis R. J., Kroeger J., Messer S. A., Tendolkar S., Diekema D. J. 2008; In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol 46:150–156 [CrossRef][PubMed]
    [Google Scholar]
19. Ramage G., López-Ribot J. L. 2005; Techniques for antifungal susceptibility testing of Candida albicans biofilms. Methods Mol Med 118:71–79[PubMed]
    [Google Scholar]
20. Stevens D. A., Espiritu M., Parmar R. 2004; Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations. Antimicrob Agents Chemother 48:3407–3411 [CrossRef][PubMed]
    [Google Scholar]
21. Tan T. Y., Tan A. L., Tee N. W., Ng L. S., Chee C. W. 2010; The increased role of non-albicans species in candidaemia: results from a 3-year surveillance study. Mycoses 53:515–521 [CrossRef][PubMed]
    [Google Scholar]
22. Wiederhold N. P., Grabinski J. L., Garcia-Effron G., Perlin D. S., Lee S. A. 2008; Pyrosequencing to detect mutations in FKS1 that confer reduced echinocandin susceptibility in Candida albicans. Antimicrob Agents Chemother 52:4145–4148 [CrossRef][PubMed]
    [Google Scholar]